Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151796 | 1.00 | KDM4E (0.57) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL3592244 | 1.00 | KDM4E (0.57) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL2633793 | 1.00 | KDM4E (0.57) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL5964063 | 1.00 | KDM4E (0.57) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL17702817 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL8209874 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL8001841 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL12265956 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL12313665 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A | |
| SCHEMBL28229063 | 0.83 | LMNA (0.56) | KDM4EADRA2CLMNAADRA2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | claimed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | claimed |
| JP-2007522197-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | claimed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20100159540-A1 | SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY | 2010-06-24 | — | — | US | disclosed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDM4E 2480/4885ADRA2C 273/4885LMNA 4494/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | KDM4E 3549/4885ADRA2C 1174/4885LMNA 3326/4885 |
| US-20100159540-A1 | SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF | ALOX5, ALOX15, ALOX15B | KDM4E 2559/4885ADRA2C 1299/4885LMNA 1092/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | KDM4E 3549/4885ADRA2C 1174/4885LMNA 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.